Evidence map›Paper›PMID 41726040›Full record

ReviewBlood science (Baltimore, Md.)2026

The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance.

Menattullah Walid, Muhammad Saboor, Shafiul Haque, Mohammad G Mohammad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood science (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Menattullah WalidDepartment of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Muhammad SaboorDepartment of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Shafiul HaqueDepartment of Nursing, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
Mohammad G MohammadDepartment of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematological malignancies, including leukemia, lymphoma, and multiple myeloma, develop within and remain dependent on a complex and dynamic tumor microenvironment (TME). Malignant cells interact continuously with the cellular and molecular components of the TME, which play a critical role in shaping disease progression, therapeutic response, and immune evasion. The TME comprises mesenchymal stromal cells, immune cells, fibroblasts, endothelial cells, and a range of signaling molecules such as chemokines, cytokines, and extracellular vesicles, embedded within a heterogeneous extracellular matrix (ECM). This integrated network, along with recently established mechanisms, establishes a supportive niche that promotes malignant cell survival, clonal evolution, immune modulation, and therapy resistance. This review examines the cellular and molecular architecture of the hematologic TME and its influence on chemoresistance and immune suppression. It further discusses therapeutic interventions that aim to disrupt or reprogram the TME, thereby restoring therapeutic sensitivity and enhancing immune-mediated clearance.

Indexed as

Chemotherapy resistanceHematological malignancyImmune evasionLeukemiaLymphomaMultiple myelomaTumor microenvironment

Identifiers

PMID41726040
PMCPMC12919749

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.